YKL-40 in patients with end-stage renal disease receiving haemodialysis
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
YKL-40 in patients with end-stage renal disease receiving haemodialysis. / Nielsen, Ture Lange; Plesner, Louis Lind; Warming, Peder Emil; Pallisgaard, Jannik Langtved; Dalsgaard, Morten; Schou, Morten; Høst, Ulla; Rydahl, Casper; Brandi, Lisbet; Køber, Lars; Johansen, Julia Sidenius; Kastrup, Jens; Iversen, Kasper Karmark.
I: Biomarkers, Bind 23, Nr. 4, 2018, s. 357-363.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - YKL-40 in patients with end-stage renal disease receiving haemodialysis
AU - Nielsen, Ture Lange
AU - Plesner, Louis Lind
AU - Warming, Peder Emil
AU - Pallisgaard, Jannik Langtved
AU - Dalsgaard, Morten
AU - Schou, Morten
AU - Høst, Ulla
AU - Rydahl, Casper
AU - Brandi, Lisbet
AU - Køber, Lars
AU - Johansen, Julia Sidenius
AU - Kastrup, Jens
AU - Iversen, Kasper Karmark
PY - 2018
Y1 - 2018
N2 - Purpose: This study aimed to determine serum YKL-40 in patients with end-stage renal disease (ESRD) on haemodialysis (HD) and to evaluate the prognostic value of serum YKL-40. Methods: Patients >18 years on maintenance HD were included. Serum YKL-40 was measured using ELISA before and after a single HD treatment. Results: A total of 306 patients were included. Median serum YKL-40 concentration was 238 µgL−1 (IQR: 193–291 µgL−1) before HD treatment and 198 µgL−1 (IQR: 147–258 µgL−1) after HD treatment, which corresponded to age-corrected 93th percentile in healthy subjects. All-cause mortality after 2.8 years was 35.9%. Patients with serum YKL-40 in the highest quartile compared with the lowest quartile had a univariate HR of 4.0 (95% CI: 2.2–7.3, < 0.001) for all-cause mortality which decreased to 2.4 (95% CI: 1.1–4.5, = 0.01) in multivariate analysis. Time-dependent receiver operating characteristic curves showed that serum YKL-40 after HD treatment had significant higher area under the curves from 90 d (p = 0.004) and throughout the rest of the follow-up period when compared to serum YKL-40 before HD treatment. Conclusion: YKL-40 was highly elevated in patients with ESRD on HD, and dialysis reduced serum YKL-40 concentrations approximately one-sixth. YKL-40 measured after dialysis was independently associated with mortality in HD patients.
AB - Purpose: This study aimed to determine serum YKL-40 in patients with end-stage renal disease (ESRD) on haemodialysis (HD) and to evaluate the prognostic value of serum YKL-40. Methods: Patients >18 years on maintenance HD were included. Serum YKL-40 was measured using ELISA before and after a single HD treatment. Results: A total of 306 patients were included. Median serum YKL-40 concentration was 238 µgL−1 (IQR: 193–291 µgL−1) before HD treatment and 198 µgL−1 (IQR: 147–258 µgL−1) after HD treatment, which corresponded to age-corrected 93th percentile in healthy subjects. All-cause mortality after 2.8 years was 35.9%. Patients with serum YKL-40 in the highest quartile compared with the lowest quartile had a univariate HR of 4.0 (95% CI: 2.2–7.3, < 0.001) for all-cause mortality which decreased to 2.4 (95% CI: 1.1–4.5, = 0.01) in multivariate analysis. Time-dependent receiver operating characteristic curves showed that serum YKL-40 after HD treatment had significant higher area under the curves from 90 d (p = 0.004) and throughout the rest of the follow-up period when compared to serum YKL-40 before HD treatment. Conclusion: YKL-40 was highly elevated in patients with ESRD on HD, and dialysis reduced serum YKL-40 concentrations approximately one-sixth. YKL-40 measured after dialysis was independently associated with mortality in HD patients.
KW - biomarker
KW - end-stage renal disease
KW - Haemodialysis
KW - inflammation
KW - mortality
KW - YKL-40
U2 - 10.1080/1354750X.2018.1428359
DO - 10.1080/1354750X.2018.1428359
M3 - Journal article
C2 - 29357700
AN - SCOPUS:85043315058
VL - 23
SP - 357
EP - 363
JO - Biomarkers
JF - Biomarkers
SN - 1354-750X
IS - 4
ER -
ID: 214133108